Our Team
Ryan Van Laar, Ph.D. – Founder & CEO
Ryan received his Ph.D. in cancer genomics from the University of Melbourne & the Peter MacCallum Cancer Centre (Australia). He has a strong background in translating genomic research into clinically actionable products and services, having held key positions at Agendia (Netherlands), Regeneron Pharmaceuticals (USA), and Signal Genetics (USA). Ryan has been instrumental in achieving regulatory clearances for multiple high-complexity oncology tests, impacting thousands of cancer patients worldwide.
Christopher Love, Ph.D. – Senior Bioinformatician
Christopher specializes in data-driven cancer genomics and biomarker discovery. With a Ph.D. in Bioinformatics from La Trobe University, Melbourne, and over a decade of experience, he focuses on interpreting complex biological datasets and developing bioinformatics pipelines for early cancer diagnosis. His expertise bridges computational and biological research to support Geneseq’s mission in precision medicine.
Lauren Coombs, BSc. – Molecular Scientist
Lauren is a molecular scientist with over 15 years of experience in molecular genetics, specializing in next-generation sequencing and diagnostic testing in clinical trials and cancer research. She has extensive expertise in advanced genomic techniques with a strong focus on advancing personalized medicine through innovative genomics-driven testing methods. Lauren holds a Bachelor of Biological Science and has completed several certifications in clinical and laboratory practices.
Ingrid Winship, MBChB, MD, FRACP, FACD, FAICD – Clinical Advisor
Ingrid is a dual-trained Clinical Geneticist and Dermatologist. She is a member of the Victorian Cancer Agency Reference Group and serves on several boards, including the Australasian College of Dermatologists and the Australian Genome Research Facility. As Chair of the Australian Health Ethics Committee, her leadership advances precision medicine and cancer research ethics.
Partnership with Australian Clinical Labs
In 2018, Australian Clinical Labs and Geneseq Biosciences partnered to launch Melaseq™, the first non-invasive melanoma test. Clinical Labs is Australia’s largest pathology provider to public hospitals and performs around 8 million episodes annually. Their molecular testing expertise complements Geneseq’s innovation in precision diagnostics.